PRF1 and hemophagocytic syndrome: Specifically, we used ruxolitinib to treat LCMV-infected perforin- or RAB27A-deficient mice (models of primary HLH), as well wild-type mice exposed to repeated injections of CpG DNA (model of secondary HLH) (11, 38).